Analysts have been eager to weigh in on the Healthcare sector with new ratings on Elevation Oncology (ELEV – Research Report), Novartis AG (CH:NOVN – Research Report) and VBI Vaccines (VBIV – Research Report).
Elevation Oncology (ELEV)
In a report issued on June 5, Marc Frahm from TD Cowen reiterated a Buy rating on Elevation Oncology. The company’s shares closed last Tuesday at $1.53, close to its 52-week low of $0.72.
According to TipRanks.com, Frahm is ranked #1208 out of 8514 analysts.
Currently, the analyst consensus on Elevation Oncology is a Strong Buy with an average price target of $7.00, which is a 360.5% upside from current levels. In a report issued on May 30, SVB Securities also upgraded the stock to Buy with a $8.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
VBI Vaccines (VBIV)
Raymond James analyst Steven Seedhouse reiterated a Buy rating on VBI Vaccines on July 10 and set a price target of $6.00. The company’s shares closed last Tuesday at $1.39, close to its 52-week low of $1.08.
According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VBI Vaccines with a $6.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ELEV:
